Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 4

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 4
---
 strategy by adding an exciting, first-of-its-kind high-capacity adenovirus (HCAd) local-delivery platform for genetic medicines. This transaction also brings us a preclinical portfolio with disease-modifying potential in prevalent musculoskeletal diseases, as well as additional research and development talent. PCRX-201 is the lead program from the HCAd platform, which we believe underscores the platform’s promise given PCRX-201’s encouraging data in osteoarthritis. Last year, we reported compelling results from a robust Phase 1 study of PCRX-201 in 72 patients with moderate to severe OA of the knee. A single intra-articular injection demonstrated unprecedented pain relief and durability across all levels of disease severity for at least two years. Driving Growth and Creating Value Looking ahead, we are excited to execute on our 5x30 strategy and believe we are well on our way to achieving a number of value-creating milestones as we maximize our commercial portfolio of three best-in-class opioid-sparing products and advance a pipeline of innovative pain relief solutions. Thank you to everyone who contributed to Pacira’s success in 2024 and for your ongoing commitment to achieving our mission. I also greatly appreciate the continued support and encouragement of our loyal stockholders and partners. Together, we are continuing to make important strides for the benefit of millions of patients we serve who deserve better pain management solutions. I look forward to the work ahead and to sharing more successes with you in the future. All the best, Chief Executive Officer TABLE OF CONTENTS Laura Brege Independent Board Chair From the Chair of the Board Dear Fellow Stockholders, As a leader in the non-opioid pain management industry, we are proud to have delivered on another year of innovation to transform the lives of patients. Under Frank’s leadership, the management team completed a comprehensive portfolio review this year to launch our go-forward strategic plan in January 2025, the 5x30 plan, which we believe will accelerate our transition into an innovative biopharmaceutical and therapeutic area leader. The recent refreshment of our executive team is a testament to the Board’s commitment to attracting best-in-industry talent to lead Pacira’s growth strategy, in conjunction with our ongoing succession planning process. In October 2024, we were pleased to welcome Shawn Cross as our new Chief Financial Officer. His more than 25 years of biotechnology and finance expertise has already supported Pacira in navigating our next phase of growth. We additionally welcomed Brendan Teehan as our new Chief Commercial Officer and Krys Cor